Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.Methods Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and <24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis.Results Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p < 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p <or= 0.05) and all-cause death (1.33, 95% CI 1.16-1.54 and 1.50, 95% CI 1.06-2.12; both p < 0.03). Severe, but not mild, cognitive dysfunction increased the risk of severe hypoglycaemia (HR 2.10, 95% CI 1.14-3.87; p = 0.018). There was no evidence of heterogeneity of treatment effects on cardiovascular outcomes in subgroups defined by cognitive function at baseline.Conclusions/interpretation Cognitive dysfunction is an independent predictor of clinical outcomes in patients with type 2 diabetes, but does not modify the effects of BP lowering or glucose control on the risks of major cardiovascular events.Trial registration ClinicalTrials.gov NCT00145925.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The person with cognitive disorders is at high risk of future severe hypoglycemic episodes, possibly because of medication errors (19,56,57)”
From Hypoglycemia (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Risk factors for hypoglycemia in people with type 2 diabetes include advancing age (18), severe cognitive impairment (19), poor health literacy (20), food insecurity (21), increased A1C (18,22), hypoglycemia unawareness (23), duration of insulin therapy, renal impairment and neuropathy (22).”
From Hypoglycemia (2018) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Treatment with statin therapy has been documented to protect against stroke, both in primary460 and secondary studies, based on data from meta-analysis36 and a single trial, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL).461”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [461]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“First, the MMSE was originally designed as a screening test for dementia and not especially for the assessment of milder degrees of cognitive dysfunction [33].”
MethodWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“Diabetes and cognitive dysfunction represent serious health problems in the ageing population, with the prevalence of both conditions projected to increase in most parts of the world [1, 2].”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 4×
“The main results have been reported previously [17, 18].”
BackgroundResultInfluentialGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332 · cited 1×
“Diabetes and cognitive dysfunction represent serious health problems in the ageing population, with the prevalence of both conditions projected to increase in most parts of the world [1, 2].”
BackgroundSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 4×
“2,777 (32.0) 572 (25.6) 44 (20.8) <0.001 HbA1c, % (SD) 7.5 (1.5) 7.6 (1.7) 7.7 (1.8) <0.001 Systolic BP, mmHg (SD) 144 (21.2) 147 (22.8) 147 (22.5) <0.001 Diastolic BP, mmHg (SD) 81 (10.8) 80 (11.3) 80 (10.7) 0.102 Serum total cholesterol, mmol/l (SD) 5.2 (1.2) 5.3 (1.2) 5.2 (1.1) 0.004 Serum creatinine, µmol/l 86.3 (…”
MethodInfluentialPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929 · cited 1×
“Cognition was defined as ‘normal’ for MMSE scores of ≥28, as ‘mild dysfunction’ for scores of 24–27, and as ‘severe dysfunction’ for scores <24 [20].”
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · cited 3×
“The main results have been reported previously [17, 18].”
BackgroundResultSelf-citationCognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049 · cited 1×
“6-fold greater risk of dementia compared with people without diabetes [7].”
BackgroundCognitive Dysfunction and Diabetes Mellitus
Kodl, C. T., & Seaquist, E. R. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0034 · Cited by 802
Insulin Sensitivity and Atherosclerosis
Howard, G., O’Leary, D. H., Zaccaro, D., Haffner, S., Rewers, M., Hamman, R., Selby, J. V., Saad, M. F., Savage, P., & Bergman, R. (1996) · Circulation · doi:10.1161/01.cir.93.10.1809 · Cited by 729
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Launer, L. J., Miller, M. E., Williamson, J. D., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M., Horowitz, K. R., Ding, J., Marcovina, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70188-0 · Cited by 574
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Biessels, G. J., Strachan, M. W. J., Visseren, F. L. J., Kappelle, L. J., & Whitmer, R. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70088-3 · Cited by 551
Hughes, D., Judge, C., Murphy, R., Loughlin, E., Costello, M., Whiteley, W., Bosch, J., O’Donnell, M. J., & Canavan, M. (2020) · JAMA · doi:10.1001/jama.2020.4249 · Cited by 472
Type 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
Srikanth, V., Sinclair, A. J., Hill-Briggs, F., Moran, C., & Biessels, G. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30118-2 · Cited by 465
Hypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443
“1) in patients with type 2 diabetes (26).”
BackgroundYaffe, K. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6176 · Cited by 441
Cognitive function, dementia and type 2 diabetes mellitus in the elderly
Strachan, M. W. J., Reynolds, R. M., Marioni, R. E., & Price, J. F. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.228 · Cited by 404
“However, other data suggest that cognitive impairment and dementia are themselves risk factors for hypoglycemia”
BackgroundCognitive function in patients with diabetes mellitus: guidance for daily care
Koekkoek, P. S., Kappelle, L. J., van den Berg, E., Rutten, G. E. H. M., & Biessels, G. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70249-2 · Cited by 393
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386
Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review
Geijselaers, S. L. C., Sep, S. J. S., Stehouwer, C. D. A., & Biessels, G. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70148-2 · Cited by 377
Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus
Baynest, H. W. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000541 · Cited by 373
Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes
Punthakee, Z., Miller, M. E., Launer, L. J., Williamson, J. D., Lazar, R. M., Cukierman-Yaffee, T., Seaquist, E. R., Ismail-Beigi, F., Sullivan, M. D., Lovato, L. C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1855 · Cited by 337
Cognitive dysfunction in diabetes: how to implement emerging guidelines
Biessels, G. J., & Whitmer, R. A. (2020) · Diabetologia · doi:10.1007/s00125-019-04977-9 · Cited by 310
Pal, K., Mukadam, N., Petersen, I., & Cooper, C. (2018) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-018-1581-3 · Cited by 276
Feinkohl, I., Aung, P. P., Keller, M., Robertson, C. M., Morling, J. R., McLachlan, S., Deary, I. J., Frier, B. M., Strachan, M. W. J., Price, J. F., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1384 · Cited by 266
Cognitive dysfunction in patients with type 2 diabetes
Reijmer, Y. D., van den Berg, E., Ruis, C., Jaap Kappelle, L., & Biessels, G. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1112 · Cited by 251
“The closed icons reflect dementia incidence according to age in the general population [71] and the open icons, the added incidence attributable to T2DM [34,166].”
BackgroundDiabetes Mellitus and Dementia
Ninomiya, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0487-z · Cited by 212
Cerebral ischemic damage in diabetes: an inflammatory perspective
Shukla, V., Shakya, A. K., Perez-Pinzon, M. A., & Dave, K. R. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0774-5 · Cited by 200
“Decreased cognitive function can also lead to an increased risk of hypoglycemia and CVD events, and thus mortality [250].”
BackgroundAn update on type 2 diabetes, vascular dementia and Alzheimer’s disease.
Exalto, L. G., Whitmer, R. A., Kappele, L. J., & Biessels, G. J. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.014 · Cited by 194
“In addition, they are more likely to experience treatment related complications, such as severe hypoglycemic episodes (Bruce et al., 2009) and are at increased risk of major cardiovascular events and death (de Galan et al., 2009).”
BackgroundFeinkohl, I., Price, J. F., Strachan, M. W. J., & Frier, B. M. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0130-5 · Cited by 182
Glycemic Management of Type 2 Diabetes Mellitus
Ismail-Beigi, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1013127 · Cited by 177
Hypoglycemia, Diabetes, and Cardiovascular Disease
Snell-Bergeon, J. K., & Wadwa, R. P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0031 · Cited by 161
“Decreased cognitive function can also lead to an increased risk of both hypoglycemia and CV events and mortality.(20) In a study examining magnetic resonance imaging of the brain in a cohort of 22 patients with T1D, brain lesions were more common in patients with T1D who had a history of repeated (five or more) hypogl…”
Cognitive impairment and risk of cardiovascular events and mortality
O'Donnell, M., Teo, K., Gao, P., Anderson, C., Sleight, P., Dans, A., Marzona, I., Bosch, J., Probstfield, J., & Yusuf, S. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs053 · Cited by 153
“An analysis of the ADVANCE trial also reported an association between MMSE score and risk of CV events, although the population was confined to patients with diabetes mellitus.(12) Our study represents that largest cohort to evaluate the association between cognitive impairment and major vascular events, includes a br…”
BackgroundResultSelf-citationHypoglycaemic episodes and risk of dementia in diabetes mellitus: 7‐year follow‐up study
Lin, C. ‐., & Sheu, W. H. ‐. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12000 · Cited by 149
Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies
Tolppanen, A.-M., Solomon, A., Soininen, H., & Kivipelto, M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120802 · Cited by 136
Review of Hypoglycemia in the Older Adult: Clinical Implications and Management
Sircar, M., Bhatia, A., & Munshi, M. N. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.004 · Cited by 153
Update on cognitive decline and dementia in elderly patients with diabetes
Bordier, L., Doucet, J., Boudet, J. M., & Bauduceau, B. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.02.002 · Cited by 136
Mattishent, K., & Loke, Y. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12587 · Cited by 123
“We identified five relevant studies that evaluated the relationship of dementia as a predictor of increased risk of hypoglycaemia (Figure 1B) [10,11,18,20,21].”
BackgroundMeneilly, G. S., Knip, A., Miller, D. B., Sherifali, D., Tessier, D., & Zahedi, A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.021 · Cited by 144
Strachan, M. W. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03199.x · Cited by 114
Lee, A. K., Rawlings, A. M., Lee, C. J., Gross, A. L., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetologia · doi:10.1007/s00125-018-4668-1 · Cited by 115
Ma, H., Jiang, T., Tang, W., Ma, Z., Pu, K., Xu, F., Chang, H., Zhao, G., Gao, W., Li, Y., et al. (2020) · Clinical Science · doi:10.1042/cs20200530 · Cited by 119
Metabolic Alterations Associated to Brain Dysfunction in Diabetes
Duarte, J. (2014) · Aging and Disease · doi:10.14336/ad.2014.1104 · Cited by 101
“Cognitive dysfunction in patients with diabetes particularly impairs the ability to control glycaemia and thus is also associated with enhanced risk of severe hypoglycaemia episodes and cardiovascular diseases, relative to patients without cognitive abnormalities [30, 31].”
BackgroundYale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Diabetes, Dementia and Hypoglycemia
Meneilly, G. S., & Tessier, D. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.006 · Cited by 109
Aung, P. P., Strachan, M. W. J., Frier, B. M., Butcher, I., Deary, I. J., Price, J. F., & on behalf of the Edinburgh Type 2 Diabetes Study Investigators (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03505.x · Cited by 96
Association between hypoglycemia and dementia in patients with type 2 diabetes
Sheen, Y., & Sheu, W. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.004 · Cited by 105
Biessels, G. J., Verhagen, C., Janssen, J., van den Berg, E., Zinman, B., Rosenstock, J., George, J. T., Passera, A., Schnaidt, S., & Johansen, O. E. (2019) · Diabetes Care · doi:10.2337/dc19-0783 · Cited by 88
Management of Type 2 Diabetes Mellitus in Older Adults
Kim, K., Kim, S. K., Sung, K. M., Cho, Y., & Park, S. W. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.336 · Cited by 99
Thein, F. S., Li, Y., Nyunt, M. S. Z., Gao, Q., Wee, S. L., & Ng, T. P. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1491779 · Cited by 88
Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
McIntosh, E. C., Nation, D. A., & Initiative, A. D. N. (2019) · Diabetes Care · doi:10.2337/dc18-1399 · Cited by 87
Meneilly, G. S., Knip, A., & Tessier, D. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.045 · Cited by 91
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
McMillan, J. M., Mele, B. S., Hogan, D. B., & Leung, A. A. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000563 · Cited by 80
Psychosoziales und Diabetes (Teil 1)
Kulzer, B., Albus, C., Herpertz, S., Kruse, J., Lange, K., Lederbogen, F., & Petrak, F. (2013) · Diabetologie und Stoffwechsel · doi:10.1055/s-0033-1335785 · Cited by 93
Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus
Yun, J., & Ko, S. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.6.423 · Cited by 83
Association of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus
Mehta, H. B., Mehta, V., & Goodwin, J. S. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw217 · Cited by 68
Ahmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2024) · Communications Medicine · doi:10.1038/s43856-023-00429-z · Cited by 82
Abdelhafiz, A. H., McNicholas, E., & Sinclair, A. J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.027 · Cited by 76
Cognitive impairment and risk of future stroke: a systematic review and meta-analysis
Lee, M., Saver, J. L., Hong, K., Wu, Y., Liu, H., Rao, N. M., & Ovbiagele, B. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.140147 · Cited by 75
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 86
Biessels, G. J., Verhagen, C., Janssen, J., van den Berg, E., Wallenstein, G., Zinman, B., Espeland, M. A., & Johansen, O. E. (2021) · Diabetologia · doi:10.1007/s00125-021-05393-8 · Cited by 55
“Cognitive dysfunction in type 2 diabetes, in particular severe forms, is an independent predictor for adverse clinical outcomes such as hypoglycaemia, cardiovascular events and death [1, 8].”
BackgroundResultDiabetes and cognitive decline
Bellia, C., Lombardo, M., Meloni, M., Della‐Morte, D., Bellia, A., & Lauro, D. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.07.006 · Cited by 64
Twig, G., Tirosh, A., Derazne, E., Haklai, Z., Goldberger, N., Afek, A., Gerstein, H. C., Kark, J. D., & Cukierman-Yaffe, T. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0798-5 · Cited by 59
“In an analysis of 11,140 individuals with type 2 diabetes who were followed for a median of 5 years there was also an inverse relationship between the MMSE score at baseline and incident CVD events that persisted after multivariate adjustment for sociodemographic variables [31].”
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 83
Chin, S. O., Rhee, S. Y., Chon, S., Baik, S. H., Park, Y., Nam, M. S., Lee, K. W., Chun, K. H., Woo, J., & Kim, Y. S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.027 · Cited by 60
“Poor cognitive function has a significant relationship with the risk of hypoglycemic events [31, 32], and the bidirectional association between hypoglycemia and dementia was demonstrated previously [20].”
BackgroundEpidemiological Evidence of the Relationship Between Diabetes and Dementia
Ninomiya, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_2 · Cited by 60
Heart health meets cognitive health: evidence on the role of blood pressure
Palta, P., Albert, M., & Gottesman, R. F. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00248-9 · Cited by 58
Ida, S., Nakai, M., Ito, S., Ishihara, Y., Imataka, K., Uchida, A., Monguchi, K., Kaneko, R., Fujiwara, R., Takahashi, H., et al. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.06.012 · Cited by 55
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 61
“macroalbuminuria is provided for the combination of perindopril and indapamide from the ADVANCE trial.(62) Of interest, serum creatinine and ESRD were not affected.”
BackgroundClayton, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.022 · Cited by 75
Psychosoziales und Diabetes (Teil 2)
Kulzer, B., Albus, C., Herpertz, S., Kruse, J., Lange, K., Lederbogen, F., & Petrak, F. (2013) · Diabetologie und Stoffwechsel · doi:10.1055/s-0033-1335889 · Cited by 65
Schwartz, S. S., Herman, M. E., Tun, M. T. H., Barone, E., & Butterfield, D. A. (2024) · BMC Medicine · doi:10.1186/s12916-024-03763-8 · Cited by 54
“Hypoglycemia is an additional serious concern with the use of exogenous insulin [82–84].”
Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis
Tuligenga, R. H. (2015) · Endocrine Connections · doi:10.1530/ec-15-0004 · Cited by 49
Abdelhafiz, A. H., & Sinclair, A. J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1135-4 · Cited by 49
Avogaro, A., Dardano, A., de Kreutzenberg, S. V., & Prato, S. D. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12319 · Cited by 49
Neurocognitive Changes and Their Neural Correlates in Patients with Type 2 Diabetes Mellitus
Lee, J. H., Choi, Y., Jun, C., Hong, Y. S., Cho, H. B., Kim, J. E., & Lyoo, I. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.2.112 · Cited by 39
Update on Insulin Therapy for Type 2 Diabetes
Donner, T. W., & Muñoz, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2202 · Cited by 49
Cognitive Dysfunction Among Adults With Type 2 Diabetes Mellitus in Karnataka, India
Yerrapragada, D. B., Rao, C. R., Karunakaran, K., & Lee, H. S. E. (2019) · Ochsner Journal · doi:10.31486/toj.18.0160 · Cited by 42
Hypoglycaemia and dementia in diabetic patients
Bauduceau, B., Doucet, J., Bordier, L., Garcia, C., Dupuy, O., & Mayaudon, H. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70476-6 · Cited by 46
Lee, Y. J., Kang, H. M., Kim, N. K., Yang, J. Y., Noh, J. H., Ko, K. S., Rhee, B. D., & Kim, D. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.2.150 · Cited by 45
Executive function, but not memory, associates with incident coronary heart disease and stroke
Rostamian, S., van Buchem, M. A., Westendorp, R. G. J., Jukema, J. W., Mooijaart, S. P., Sabayan, B., & de Craen, A. J. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001895 · Cited by 40
“Current evidence, in line with this hypothesis, indicates that poor general cognitive function associates with cardiovascular events, stroke, and mortality.(12,13) However, the independent link between domainspecific cognitive deficits and risk of cardiovascular outcomes is not fully understood.”
ResultDiabetes Management in Older Adults With Chronic Kidney Disease
Clemens, K. K., O’Regan, N., & Rhee, J. J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1128-3 · Cited by 42
Isop, L. M., Neculau, A. E., Necula, R. D., Kakucs, C., Moga, M., & Dima, L. (2023) · Pharmaceuticals · doi:10.3390/ph16121714 · Cited by 41
Ikeda, Y., Kubo, T., Oda, E., Abe, M., & Tokita, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12778 · Cited by 39
Nilsson, M. S. D., Jensen, N. J., Gejl, M., Bergmann, M., Storgaard, H., Zander, M., Miskowiak, K. W., & Rungby, J. (2019) · Diabetologia · doi:10.1007/s00125-019-4964-4 · Cited by 38
Diabetes, dysglycemia and cognitive dysfunction
Cukierman‐Yaffe, T. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2507 · Cited by 39
“In the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE), study people with diabetes with severe cognitive impairment (MMSE<=23) had a statistically significant greater risk of developing severe hypoglycaemia [34].”
BackgroundMitochondrial transfer - a novel promising approach for the treatment of metabolic diseases
Chen, R., & Chen, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1346441 · Cited by 38
Leng, X., Espeland, M. A., Manson, J. E., Stefanick, M. L., Gower, E. W., Hayden, K. M., Limacher, M. C., Vaughan, L., Robinson, J. G., Wallace, R. B., et al. (2017) · The Journals of Gerontology Series A · doi:10.1093/gerona/glx138 · Cited by 33
Cognition matters in cardiovascular disease and heart failure
Angermann, C. E., Frey, A., & Ertl, G. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs128 · Cited by 32
“In humans, an association between the total burden of CVD and cognitive deterioration was reported.(5,6) Further, the degree of CI correlated with the severity of left ventricular systolic dysfunction in HF patients.”
BackgroundMimenza-Alvarado, A. J., Jiménez-Castillo, G. A., Yeverino-Castro, S. G., Barragán-Berlanga, A. J., Pérez‐Zepeda, M. U., Ávila‐Funes, J. A., & Aguilar-Navarro, S. G. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01827-x · Cited by 31
Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE
Chalmers, J. P., & Arima, H. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181d26469 · Cited by 30
Self-citationSala, L. L., & Pontiroli, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910643 · Cited by 29
“Severe hypoglycemia occurred about two to three times more often in the intensive care unit (ICU), and is more common in people with low cognitive function [28].”
BackgroundOptimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?
Mathur, S., Zammitt, N. N., & Frier, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0247-7 · Cited by 30
Muneer, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_534 · Cited by 28
Cognitive disorders in diabetic patients
Koekkoek, P. S., Rutten, G. E. H. M., & Biessels, G. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00011-4 · Cited by 28
Sugimoto, T., Tokuda, H., Miura, H., Kawashima, S., Ando, T., Kuroda, Y., Matsumoto, N., Fujita, K., Uchida, K., Kishino, Y., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14866 · Cited by 26
Cognitive Dysfunction in Older Adults with Type 2 Diabetes
Sinclair, A. J., & Abdelhafiz, A. H. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.002 · Cited by 26
van Dieren, S., Kengne, A. P., Chalmers, J. P., Beulens, J. W. J., Cooper, M. E., Grobbee, D. E., Harrap, S. B., Mancia, G., Neal, B. C., Patel, A. A., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.002 · Cited by 26
“[21] de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, et al.”
BackgroundSelf-citationSugimoto, T., Araki, A., Fujita, H., Fujita, K., Honda, K., Inagaki, N., Ishida, T., Kato, J., Kishi, M., Kishino, Y., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.117 · Cited by 23
Geriatric Syndromes in Older Adults with Diabetes
Neumiller, J. J., & Munshi, M. N. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.004 · Cited by 23
Diabetic Cognitive Dysfunction: From Bench to Clinic
Zhou, J., Zhang, Z., Zhou, H., & Qian, G. (2020) · Current Medicinal Chemistry · doi:10.2174/1871530319666190206225635 · Cited by 23
Malik, A. H., Yandrapalli, S., Aronow, W. S., Jain, D., Frishman, W. H., Panza, J. A., & Cooper, H. A. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000276 · Cited by 21
“We know from animal studies that recurrent hypoglycemia worsens ischemic damage to the brain, leading to cognitive decline which has been shown to increase the risk for future cardiovascular events.(26,27) Furthermore, extreme low levels of glucose activate counter-regulatory defense mechanisms that, in turn, elevate…”
BackgroundDaniel, J. M., Lindsey, S. H., Mostany, R., Schrader, L. A., & Zsombok, A. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101068 · Cited by 20
“…progression to Alzheimer’s disease in diabetic patients treated with anti-diabetic agents (Geijselaers et al., 2015, Areosa Sastre et al., 2017, de Galan et al., 2009), suggesting pre-existing conditions impair metabolic target (glucose homeostasis and insulin signaling) treatment…”
Background
Metadata
- Authors
- for the ADVANCE Collaborative group, de Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D. E., Hackett, M., Hamet, P., Heller, S. R., Lisheng, L., MacMahon, S., Mancia, G., Neal, B., Pan, C. Y., Patel, A., Poulter, N., Travert, F., & Woodward, M.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- National Health Service (GB)
- St Mary's Hospital (GB)
- Université Pierre-et-Marie-Curie (FR)
- Corresponding author
- Zoungas, S.
- ORCID
- Venue
- Diabetologia
- Published
- 2009-08-18
- Volume
- 52
- Issue
- 11
- Pages
- 2328-2336
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1980054867
- Cited by
- 243
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 16 · 2021: 14 · 2020: 16 · 2019: 17 · 2018: 22 · 2017: 9 · 2016: 14 · 2015: 16 · 2014: 13 · 2013: 18 · 2012: 15
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Servier
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, cognitive impairment, cardiovascular disease, cardiovascular mortality, all-cause mortality, hypoglycemia, metformin, glimepiride, blood pressure reduction, glycemic control, treatment effect heterogeneity, Mini-Mental State Examination, ADVANCE trial, cardiovascular risk stratification, cognitive screening, stroke risk, myocardial infarction risk
- MeSH terms
- Aged, Antihypertensive Agents, Cognition, Cognition Disorders, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Combinations, Drug Therapy, Combination, Educational Status, Female, Gliclazide, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Male, Mental Status Schedule, Myocardial Infarction, Risk Factors, Stroke, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.